SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Oklo, Inc. engages in the development of fission reactors. It provides clean energy through the design and deployment of fast fission power plants. The company was founded by Jacob DeWitte and Caroline Cochran on July 3, 2013 and is headquartered in Santa Clara, CA.

Oklo Inc. - Ordinary Shares - Class A

Oklo Inc.

Oklo Inc. is trending due to growing excitement around its potential role in powering AI data centers and a recent partnership, driving speculation and retail investor interest. The community is actively discussing its high valuation relative to its pre-revenue status, debating whether it's a sustainable investment or a speculative bubble. Some traders are noting technical breakouts and potential for further gains, while others remain cautious, citing the risks associated with its long-term commercialization timeline.

AGM Group Holdings, Inc. is a technology company, which engages in the provision of financial solutions. It focuses on the research and development of blockchain-oriented ASIC chip, production of encryption mining machines, and financial technology software services. Its products and services include technology hardware research and development, and assembling and sales of technology hardware. The company was founded by Zhen Tao Jiang and Wen Jie Tang on April 27, 2015 and is headquartered in Hong Kong.

AGM Group Holdings Inc - Ordinary Shares - Class A

AGMH is trending due to news of a completed subsidiary sale for $57.45 million, significantly exceeding its market cap, sparking community excitement and a potential short squeeze. Traders are actively discussing entry and exit points, with some eyeing price targets, while also pointing to the stock's volatility and potential for quick gains. The focus remains on AGMH's low float and potential for further upward movement amidst broader discussions of Chinese stocks and market momentum.

Brera Holdings Plc engages in the business of football division progression, global football player transfer service, sponsorship services, football school services, and consulting services on football projects. The company was founded on June 30, 2022 and is headquartered in Dublin, Ireland.

Brera Holdings PLC - Ordinary Shares - Class B

Brera Holdings PLC

BREA is trending due to news of a $300M private investment for a Solana-based digital asset treasury, drawing attention from investors like ARK Invest. Community discussions revolve around potential price targets and the possibility of a short squeeze, with some comparing it to other crypto treasury plays. The stock's low float and news-driven momentum contribute to its volatile price action and heightened interest.

SoFi Technologies, Inc. is a financial service platform, which engages in the provision of student loan refinancing options to the private student loan market. It operates through the following segments: Lending, Technology Platform, and Financial Services. The Lending segment offers personal loans, student loans, home loan products, and related servicing activities. The Technology Platform segment focuses on technology products and solutions revenue. The Financial Services segment includes the SoFi Money product, SoFi Invest product, SoFi Credit Card product, SoFi Relay personal finance management product, and other financial services such as lead generation and content for other financial services institutions. The company was founded in 2011 and is headquartered in San Francisco, CA.

SoFi Technologies Inc

SOFI is trending amid optimism surrounding potential interest rate cuts and a possible inclusion in the S&P 500, fueling discussions of a short squeeze. The community is actively debating whether the stock will break through resistance levels and reach new all-time highs, or if profit-taking will lead to a pullback. Bullish sentiment is further supported by analyst upgrades and the anticipation of strong future earnings reports.

Quantum Computing, Inc. engages in developing novel algorithms and solutions utilizing quantum and quantum-inspired computing to solve difficult problems in various industries. It leverages its expertise in finance, computing, security, mathematics, and physics to develop commercial applications for the financial, security, and government sectors. The company was founded on July 25, 2001 and is headquartered in Hoboken, NJ.

Quantum Computing Inc

QUBT is trending due to a mix of factors, including a recently raised price target and discussion of potential government contracts. Community members are actively debating the company's valuation and future growth prospects within the quantum computing sector, comparing QUBT to its peers. Some traders anticipate a continued upward trend, while others express caution, citing high valuation metrics and mixed earnings results.

WhiteFiber, Inc. provides AI and HPC infrastructure & cloud and data center solutions. It operates through the following segments: Cloud Services and Colocation Services. The Cloud Services segment offers computing services to support generative AI workstreams. The Colocation Services segment provides customers with physical space, power and cooling within the data center facility. The company was founded on August 15, 2024 and is headquartered in New York, NY.

Whitefiber Inc.

WhiteFiber, Inc.

WhiteFiber ($WYFI) is trending as investors discuss its potential in the AI data center space following its recent IPO. Community members are pointing to the company's low float and potential connection to Tom Lee as catalysts, while also highlighting Bit Digital's ($BTBT) stake in WhiteFiber and the potential for strategic moves. The focus is on upcoming news and contracts related to WhiteFiber's AI infrastructure and data center capabilities.

Universe Pharmaceuticals, Inc. is a pharmaceutical company. The firm is focused on the manufacturing, marketing, sales, and distribution of traditional Chinese medicine derivative products. It also sells biomedical drugs, medical instruments, traditional Chinese medicine Pieces, and dietary supplements manufactured by third-party pharmaceutical companies. The company was founded on March 2, 1998 and is headquartered in Ji'an, China.

Universe Pharmaceuticals INC

UPC is trending due to its low float and high cash per share, leading to community speculation about a potential squeeze. Some traders are comparing it to previous runners like $BREA and $AGMH, while others anticipate news related to crypto.

CleanSpark, Inc. is a bitcoin mining technology company, which engages in the management of data centers. Its operations include College Park, Norcross, Washington, Sandersville, Dalton, and Massena. The company was founded by S. Matthew Schultz and Bryan Huber on October 15, 1987 and is headquartered in Henderson, NV.

Cleanspark Inc

Cleanspark is trending amid increasing community excitement around its potential move into AI data centers and high-performance computing, with analysts suggesting a significant revaluation could be on the horizon. Traders are closely watching key resistance levels, fueled by bullish sentiment and anticipation that CLSK will catch up to its peers in the mining sector. The community highlights the company's strong fundamentals, low debt, and significant short interest as additional factors driving current interest.

Aquestive Therapeutics, Inc. engages in the identifying, developing, and commercializing differentiated products to address unmet medical needs and to solve patients’ therapeutic problems. Its product pipeline include Libervant, AQST-108, AQST-305, Suboxone and Zuplenz. The company was founded in January 2004 and is headquartered in Warren, NJ.

Aquestive Therapeutics Inc

Aquestive Therapeutics ($AQST) is trending amid increased community discussion fueled by a recent mention on Cramer's Mad Money and anticipation surrounding their drug Anaphylm.  The community is actively debating the potential impact of a positive FDA decision (PDUFA date 01/31/2026) and speculating on buyout possibilities. Bullish sentiment is countered by some skepticism regarding product pipeline and revenue.

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Network and Edge (NEX), Mobileye, Accelerated Computing Systems and Graphics (AXG), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The NEX segment offers computing system solutions from inflexible fixed-function hardware to general-purpose compute, acceleration, and networking devices running cloud native software on programmable hardware. The Mobileye segment develops driving assistance and self-driving solutions. The AXG segment provides products and technologies designed to help customers solve the toughest computational problems. Its products include CPUs for high-performance computing and GPUs targeted for a range of workloads and platforms, from gaming and content creation on client devices to delivering media and gaming in the cloud, and the most demanding high-performance computing and AI workloads on supercomputers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968 and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is trending due to Nvidia's significant investment and partnership, sparking optimism about Intel's role in AI and chip manufacturing. The community is discussing potential foundry deals and future collaborations with companies like Tesla and Apple. Some analysts have upgraded their price targets, while others remain skeptical, focusing on Intel's execution and competitive challenges.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

KalVista Pharmaceuticals, Inc. (KALV) Reports Q1 Loss, Lags Revenue Estimates

KalVista Pharmaceuticals (KALV) delivered earnings and revenue surprises of -23.08% and -20.91%, respectively, for the quarter ended July 2025. Do the numbers hold clues to what lies ahead for the stock?

KALV Stock Moves More Than 30% in a Week: What Is Driving This Rally?

KalVista jumps 36% in a week after the FDA clears Ekterly, the first oral on-demand therapy for hereditary angioedema.

KalVista Pharmaceuticals, Inc. (KALV) on Monday said that the U.S. Food and Drug Administration (FDA) has approved its drug Ekterly for the treatment of acute attacks of hereditary angioedema in adults and children aged 12 years and older.<a href="https://stocktwits.com/symbol/KALV">KalVista</a>’s shares were up over 17% in pre-market trading.Hereditary angioedema (HAE) is a rare genetic disease caused by deficiency or dysfunction of a protein called the C1 esterase inhibitor, where patients experience painful and debilitating attacks of tissue swelling in various locations of the body that can be life-threatening depending on the area affected.Ekterly is the first and only oral on-demand treatment for HAE, KalVista <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.kalvista.com/news-releases/news-release-details/kalvista-pharmaceuticals-announces-fda-approval-ekterlyr">said</a>, setting it apart from other on-demand HAE treatment options approved in the U.S., which require intravenous or subcutaneous administration.Even with the use of long-term prophylaxis as a preventative therapy, most people living with HAE continue to have unpredictable attacks and require on-demand access to medication, the company added.KalVista will launch Ekterly in the U.S. immediately, and physicians can begin writing prescriptions on Monday.The approval was based on results from a late-stage study in 136 patients, showing that Ekterly achieved significantly faster symptom relief, a reduction in attack severity, and an increase in attack resolution compared to the placebo. The results also showed that the drug was well-tolerated, with a safety profile similar to that of the placebo.A later study also showed that Ekterly enabled patients to treat attacks in a median of 10 minutes following onset.On Stocktwits, retail sentiment around KalVista jumped from ‘neutral’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘high’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:626/67;" src="https://news.stocktwits-cdn.com/Screenshot_2025_07_07_at_8_56_04_AM_png_8e1123c17a.webp" alt="KALV's Sentiment Meter and Message Volume as of 8:55 a.m. ET on July 7, 2025 | Source: Stocktwits" width="626" height="67"><figcaption>KALV's Sentiment Meter and Message Volume as of 8:55 a.m. ET on July 7, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user expressed optimism for the stock hitting as high as $50 upon the news.<stembedurl>https://stocktwits.com/fzriderz/message/620039415</stembedurl>KALV stock is up by over 41% this year and down by about 2% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/shell-signals-earnings-dip-in-trading-in-q2-but-refining-margin-to-improve/chFthjLR5PR">Shell Signals Earnings Dip In Trading In Q2, But Refining Margin To Improve</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

KalVista Stock Soars Pre-Market On FDA Approval For Drug In Treating Swelling Disorder: Retail’s Elated

Ekterly is the first and only oral on-demand treatment for hereditary angioedema, KalVista said, setting it apart from other on-demand treatment options approved in the U.S., which require intravenous or subcutaneous administration. 

Equity

Ekterly is the first and only oral on-demand treatment for hereditary angioedema, KalVista said, setting it apart from other on-demand treatment options approved in the U.S., which require intravenous or subcutaneous administration. 


KalVista Pharmaceuticals to Present at Upcoming Investor Conferences

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the Company will participate in a fireside chat at each of the following investor conferences: TD Cowen 45th Annual Health Care...

KalVista Pharmaceuticals to Present New Sebetralstat Data at the American Academy of Allergy, Asthma & Immunology 2025 Annual Meeting

KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced that six abstracts have been accepted for presentation at the American Academy of Allergy, Asthma & Immunology (AAAAI) / World Allergy...

KalVista Pharmaceuticals Presents New Sebetralstat Data at the Western Society of Allergy, Asthma & Immunology 2025 Annual Meeting

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced the presentation of novel data related to long-term prophylaxis and sebetralstat at the Western Society of Allergy, Asthma & Immunology...

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the compensation committee of KalVistas board of directors granted fifty-two newly-hired employees inducement options to purchase...

KalVista Announces Orphan Drug Designation and NDA Submission for Sebetralstat in Japan for Hereditary Angioedema

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that Japans Ministry of Health, Labour and Welfare (MHLW) has granted sebetralstat Orphan Drug Designation. The Company has also...

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) today announced that the compensation committee of KalVistas board of directors granted nine newly-hired employees inducement options to purchase an...

KalVista Appoints Jeb Ledell as Chief Operating Officer

KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that Jeb Ledell has joined the Company as Chief Operating Officer (COO). Mr. Ledell is an accomplished public company COO with a track...

KalVista Pharmaceuticals, Inc. is a clinical stage pharmaceutical company, which engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with significant unmet need. Its product candidates are inhibitors of plasma kallikrein being developed for two indications: Sebetralstat for HAE and Factor XIIa. The company was founded by T. Andrew Crockett, Edward P. Feener, and Lloyd Paul Aiello on March 26, 2004 and is headquartered in Framingham, MA.

KalVista Pharmaceuticals Inc

Just the one

Three

Four

The Fed just cut rates. How many cuts do you expect in all of 2025? 
 
*Powered by Polymarket

Fiscal Period	Estimated	Reported	Surprise	Result
Q2 '25	-$1.00	--	--	N/A
Q1 '25	-$0.95	-$1.12	-17.48%	MISSED
Q4 '24	-$0.80	-$0.99	-23.92%	MISSED
Q3 '24	-$0.87	-$0.92	-6.24%	MISSED
Q2 '24	-$0.91	-$0.91	--	EXPECTED

KALV
KalVista Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest Earnings Results: Q1 '25

Historical Earnings

Latest KALV News

KALV KalVista Pharmaceuticals Inc